Nefopam information

Nefopam
Clinical data
Trade names	nefopam medisol
AHFS/Drugs.com	International Drug Names
Routes of; administration	intramuscular, intravenous
ATC code	N02BG06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	Low
Protein binding	70–75% (mean 73%)
Metabolism	Liver (N-demethylation, others)
Metabolites	Desmethylnefopam, others
Elimination half-life	Nefopam: 3–8 hours; Desmethylnefopam: 10–15 hours
Excretion	Urine: 79.3%; Feces: 13.4%
Identifiers
	IUPAC name (RS)-5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine;
CAS Number	13669-70-0 ;
PubChem CID	4450;
ChemSpider	4295 ;
UNII	4UP8060B7J;
KEGG	D08258 ;
ChEBI	CHEBI:88316 ;
CompTox Dashboard (EPA)	DTXSID2048535 ;
ECHA InfoCard	100.033.757
Chemical and physical data
Formula	C17H19NO
Molar mass	253.345 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCOC(C2=CC=CC=C2C1)C3=CC=CC=C3;
	InChI InChI=1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3 ; Key:RGPDEAGGEXEMMM-UHFFFAOYSA-N ;
	(what is this?) (verify)

Nefopam, sold under the brand name Acupan among others, is a centrally acting, non-opioid painkilling medication, that is primarily used to treat moderate to severe pain.^[3]

Nefopam acts in the brain and spinal cord to relieve pain via novel mechanisms: antinociceptive effects from triple monoamine reuptake inhibition, and antihyperalgesic activity through modulation of glutamatergic transmission.^[4]

^ ^a ^b ^c ^d ^e ^f ^g ^h Sanga M, Banach J, Ledvina A, Modi NB, Mittur A (November 2016). "Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 46 (11): 1001–16. doi:10.3109/00498254.2015.1136989. PMID 26796604. S2CID 34603935.
^ Seyffart G (6 December 2012). Drug Dosage in Renal Insufficiency. Springer Science & Business Media. pp. 407–. ISBN 978-94-011-3804-8.
^ Brayfield A, ed. (27 October 2016). "Nefopam hydrochloride". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 4 September 2017.
^ Cite error: The named reference RevPharm2016 was invoked but never defined (see the help page).

[pmid26796604-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h Sanga M, Banach J, Ledvina A, Modi NB, Mittur A (November 2016). "Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 46 (11): 1001–16. doi:10.3109/00498254.2015.1136989. PMID 26796604. S2CID 34603935.

[Seyffart2012-2] Seyffart G (6 December 2012). Drug Dosage in Renal Insufficiency. Springer Science & Business Media. pp. 407–. ISBN 978-94-011-3804-8.

[MD-3] Brayfield A, ed. (27 October 2016). "Nefopam hydrochloride". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 4 September 2017.

[RevPharm2016-4] Cite error: The named reference RevPharm2016 was invoked but never defined (see the help page).

Nefopam information

and 28 Related for: Nefopam information

Nefopam

Analgesic

Methamphetamine

Cocaine

Modafinil

Tachycardia

Postanesthetic shivering

Capsaicin

Paracetamol

Oxycodone

Bupropion

Carfentanil

Cyclobenzaprine

MDMA

Dopamine reuptake inhibitor

Coca

Diclofenac

Menthol

Crack cocaine

Ketamine

Fentanyl

Tesofensine

Pantothenic acid

Datura stramonium

Hyoscine butylbromide

Metamizole

Cannabis

Dimenhydrinate